BIRC5 and ovarian carcinoma: In summary, we are first to show that multiepitope immunotherapy combining tumor antigens p53, SP17, survivin, WT1, and/or NY-ESO-1 might be a promising new therapeutic vaccination strategy in ovarian cancer.